ClearPoint Neuro Inc vs Microsoft — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Microsoft trades at $501.11 (market cap $3.76T). The key difference: Microsoft is far larger — about 8465.8× ClearPoint Neuro Inc's market cap, and Microsoft pays a 0.72% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MSFT | |
|---|---|---|
Market Cap | $444.14M | $3.76T |
Sector | Health | Technology |
52-Week High | $29.60 | $542.07 |
52-Week Low | $8.66 | $352.83 |
Enterprise Value | $478.72M | $3.74T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Microsoft (MSFT) trades at $506.06, up 1.21% today, near its pivot point of $507. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $4.74 versus $4.24 expected. Revenue growth accelerated to $281.72B in 2025, with a net income margin of 40.31%. Analysts maintain an 80.49% buy rating, citing AI leadership via Azure and Copilot.
Outlook remains positive with a consensus price target of $553.70, though risks include high capital expenditures and competitive pressures in AI. The stock's valuation multiples like P/E of 28.19 are elevated, requiring sustained execution. Near-term support lies at $500, with resistance at $513.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →